Salicylic acid

Description

The product is identified by SPL Code 34089-3 and is presented as a white to off-white, round, biconvex tablet, which is debossed with "A" on one side and "123" on the other. Each tablet contains 500 mg of Acetaminophen. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide yellow.

Uses and Indications

This drug is indicated for external use only. There are no teratogenic effects associated with its use, nor are there any nonteratogenic effects reported.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should ensure that the medication is applied exclusively to the affected area of the skin. Prior to application, the area should be cleaned and dried thoroughly.

The recommended dosage and frequency of administration will depend on the specific condition being treated. It is essential to follow the prescribed dosing regimen, which may vary based on individual patient needs and response to therapy.

Patients should be advised to apply the medication as directed, avoiding contact with eyes, mucous membranes, and open wounds. In the event of accidental contact, the area should be rinsed thoroughly with water.

Healthcare professionals should monitor patients for any adverse reactions and adjust the treatment plan as necessary.

Contraindications

Use of this product is contraindicated in the following situations:

• The product should be kept out of reach of children to prevent accidental ingestion.

• Swallowing the product is contraindicated due to potential adverse effects.

• Use is contraindicated if signs of irritation or rash occur, necessitating immediate discontinuation of the product.

Proper hand hygiene is recommended prior to use to ensure optimal results.

Warnings and Precautions

It is imperative to keep this product out of reach of children. The product should not be swallowed, and proper hand hygiene is essential prior to use to ensure optimal results.

In the event of any signs of irritation or rash, it is crucial to discontinue use immediately and consult a healthcare professional. The product should be stored in a cool and dry place to maintain its efficacy and safety.

No specific general precautions or laboratory tests are recommended for this product.

Side Effects

Patients should be monitored for signs of irritation or rash during treatment. If such symptoms occur, it is recommended to discontinue use immediately. This precaution is essential to ensure patient safety and to mitigate any potential adverse reactions associated with the product.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Corn Remover Pads. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this product out of reach of children to prevent accidental ingestion or misuse. It is important to discontinue use if any irritation occurs during application. This product is intended for external use only and should not be applied to broken skin or mucous membranes.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or any special precautions that should be taken. Healthcare professionals are advised to consider the lack of data when prescribing this medication to pregnant patients and to weigh the potential risks and benefits. Women of childbearing potential should be counseled accordingly.

Lactation

There is no information available regarding the use of this drug in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the understanding of the compound's potential effects in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. It is important to instruct patients not to swallow the product, as it is not intended for ingestion.

Patients should be informed about the necessity of cleaning their hands before using the product to ensure optimal results. Additionally, healthcare providers should counsel patients to discontinue use immediately if any signs of irritation or rash occur, emphasizing the importance of monitoring for adverse reactions.

Lastly, patients should be reminded to store the product in a cool and dry place to maintain its efficacy and safety.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and protected from light exposure. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Corn Remover Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)